Insider · CIK 0001429260
Fortress Biotech, Inc.
Files at ATXI (AVENUE THERAPEUTICS, INC.), CKPT (Checkpoint Therapeutics, Inc.), MBIO (MUSTANG BIO, INC.). First filing Jun 3, 2025, latest Jun 3, 2025.
In brief
Fortress Biotech, Inc. files SEC Form 4 as 10% owner at CKPT (Checkpoint Therapeutics, Inc.), and also at ATXI (AVENUE THERAPEUTICS, INC.), MBIO (MUSTANG BIO, INC.). Since Jun 3, 2025, Fortress Biotech, Inc. has reported 0 open-market buys worth $0 and 1 open-market sell worth $129k, the latest filed on Jun 3, 2025.
A track record needs three past buys with six months of prices behind them; Fortress Biotech, Inc. has 0, so none is measured yet.
The newest scored trade: sold $129k of CKPT on May 29, 2025, filed Jun 3, 2025, scored 23 (weak).
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 23Weak | CKPTsell Checkpoint Therapeutics, Inc. | $129k 100,000 shares | -2% | - |
Transactions
Every row this insider has filed, 11 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 2, 2026 | ATXI AVENUE THERAPEUTICS, INC. | AGrant or award COMMON STOCK, PAR VALUE $0.0001 | +111,209 | $0.00 | $0 | 439,733 | Jan 6, 2026 |
| Jan 2, 2026 | MBIO MUSTANG BIO, INC. | AGrant or award COMMON STOCK, PAR VALUE $0.0001 | +278,385 | $0.00 | $0 | 536,577 | Jan 5, 2026 |
| Sep 29, 2025 | MBIO MUSTANG BIO, INC. | AGrant or award COMMON STOCK, PAR VALUE $0.0001 | +59,334 | $0.00 | $0 | 258,192 | Oct 1, 2025 |
| May 29, 2025 | CKPT Checkpoint Therapeutics, Inc. | SOpen-market sale COMMON STOCK, PAR VALUE $0.0001 | -100,000 | $1.29 | $129k | 6,122,249 | Jun 3, 2025 |
| May 30, 2025 | CKPT Checkpoint Therapeutics, Inc. | DDisposition to issuer COMMON STOCK, PAR VALUE $0.0001 | -6,122,249 | $4.10 | $25M | 0 | Jun 3, 2025 |
| May 30, 2025 | CKPT Checkpoint Therapeutics, Inc. | DDisposition to issuer CLASS A COMMON STOCK, PAR VALUE $0.0001derivative | -700,000 | $0.00 | $0 | 0 | Jun 3, 2025 |
| Mar 31, 2025 | ATXI AVENUE THERAPEUTICS, INC. | AGrant or award COMMON STOCK, PAR VALUE $0.0001 | +33,724 | $0.00 | $0 | 328,524 | Apr 2, 2025 |
| Mar 31, 2025 | MBIO MUSTANG BIO, INC. | AGrant or award COMMON STOCK, PAR VALUE $0.0001 | +67,806 | $0.00 | $0 | 198,858 | Apr 2, 2025 |
| Feb 26, 2025 | CKPT Checkpoint Therapeutics, Inc. | AGrant or award COMMON STOCK, PAR VALUE $0.0001 | +18,500 | $0.00 | $0 | 6,222,249 | Feb 27, 2025 |
| Dec 31, 2024 | CKPT Checkpoint Therapeutics, Inc. | AGrant or award COMMON STOCK, PAR VALUE $0.0001 | +81,407 | $0.00 | $0 | 3,816,941 | Jan 3, 2025 |
| Jan 1, 2025 | CKPT Checkpoint Therapeutics, Inc. | AGrant or award COMMON STOCK, PAR VALUE $0.0001 | +2,386,808 | $0.00 | $0 | 6,203,749 | Jan 3, 2025 |
Questions about Fortress Biotech, Inc.
Answered from the filings on this page, as of the latest one.
Is Fortress Biotech, Inc. buying or selling?
Not in the last 12 months. Fortress Biotech, Inc.'s latest open-market trade on SEC Form 4 was sold $129k of CKPT on May 29, 2025.
How did Fortress Biotech, Inc.'s past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Fortress Biotech, Inc. has 0.
Where does Fortress Biotech, Inc. file Form 4?
Fortress Biotech, Inc. has filed Form 4 at CKPT (Checkpoint Therapeutics, Inc.); ATXI (AVENUE THERAPEUTICS, INC.); MBIO (MUSTANG BIO, INC.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.